| Dr Utsav Ketan Bansal, MD | |
|
20801 Biscayne Blvd Ste 203, Aventura, FL 33180-1492 | |
| (305) 682-2580 | |
| (305) 705-1677 |
| Full Name | Dr Utsav Ketan Bansal |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 7 Years |
| Location | 20801 Biscayne Blvd Ste 203, Aventura, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851822936 | NPI | - | NPPES |
| 119832100 | Medicaid | FL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | ME160533 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Memorial Regional Hospital | Hollywood, FL | Hospital |
| Memorial Hospital West | Pembroke pines, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| South Broward Hospital District | 8123927373 | 534 |
News Archive
The U.S. Food and Drug Administration (FDA) has issued a public health advisory outlining new safety information, including revised product labeling about erythropoiesis-stimulating agents (ESAs), widely-used drugs for the treatment of anemia.
A long non-coding RNA (lincRNA) - called lincRNA-EPS - responsible for regulating innate immunity has been identified by a team of scientists at the University of Massachusetts Medical School.
A new study published in March 2020 in the journal PLOS ONE reports that the online version of a well-respected program that counsels infertile women achieved the same level of success as the person-to-person equivalent. This was true about both the reduction in emotional distress and the increase in pregnancy rates.
Coronary CTA offers a low cost, non-invasive alternative to conventional angiography for evaluating patients who are suspected of having coronary artery disease; true even if the patients have calcified coronary artery plaques, according to a study performed at the Thomas Jefferson University Hospital, Philadelphia, PA.
Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity, today presented dose optimization data from its Phase 2 clinical study of otelixizumab in subjects with type 1 diabetes. Otelixizumab is a targeted T-cell immunomodulator currently being evaluated in DEFEND, a Phase 3 clinical study in subjects with new-onset autoimmune type 1 diabetes.
› Verified 3 days ago
| Entity Name | South Broward Hospital District |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669713673 PECOS PAC ID: 8123927373 Enrollment ID: O20130618000353 |
News Archive
The U.S. Food and Drug Administration (FDA) has issued a public health advisory outlining new safety information, including revised product labeling about erythropoiesis-stimulating agents (ESAs), widely-used drugs for the treatment of anemia.
A long non-coding RNA (lincRNA) - called lincRNA-EPS - responsible for regulating innate immunity has been identified by a team of scientists at the University of Massachusetts Medical School.
A new study published in March 2020 in the journal PLOS ONE reports that the online version of a well-respected program that counsels infertile women achieved the same level of success as the person-to-person equivalent. This was true about both the reduction in emotional distress and the increase in pregnancy rates.
Coronary CTA offers a low cost, non-invasive alternative to conventional angiography for evaluating patients who are suspected of having coronary artery disease; true even if the patients have calcified coronary artery plaques, according to a study performed at the Thomas Jefferson University Hospital, Philadelphia, PA.
Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity, today presented dose optimization data from its Phase 2 clinical study of otelixizumab in subjects with type 1 diabetes. Otelixizumab is a targeted T-cell immunomodulator currently being evaluated in DEFEND, a Phase 3 clinical study in subjects with new-onset autoimmune type 1 diabetes.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Utsav Ketan Bansal, MD 2900 Corporate Way, Door D, Miramar, FL 33025-3925 Ph: (954) 276-5685 | Dr Utsav Ketan Bansal, MD 20801 Biscayne Blvd Ste 203, Aventura, FL 33180-1492 Ph: (305) 682-2580 |
News Archive
The U.S. Food and Drug Administration (FDA) has issued a public health advisory outlining new safety information, including revised product labeling about erythropoiesis-stimulating agents (ESAs), widely-used drugs for the treatment of anemia.
A long non-coding RNA (lincRNA) - called lincRNA-EPS - responsible for regulating innate immunity has been identified by a team of scientists at the University of Massachusetts Medical School.
A new study published in March 2020 in the journal PLOS ONE reports that the online version of a well-respected program that counsels infertile women achieved the same level of success as the person-to-person equivalent. This was true about both the reduction in emotional distress and the increase in pregnancy rates.
Coronary CTA offers a low cost, non-invasive alternative to conventional angiography for evaluating patients who are suspected of having coronary artery disease; true even if the patients have calcified coronary artery plaques, according to a study performed at the Thomas Jefferson University Hospital, Philadelphia, PA.
Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity, today presented dose optimization data from its Phase 2 clinical study of otelixizumab in subjects with type 1 diabetes. Otelixizumab is a targeted T-cell immunomodulator currently being evaluated in DEFEND, a Phase 3 clinical study in subjects with new-onset autoimmune type 1 diabetes.
› Verified 3 days ago
Boris V Klopukh, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 21110 Biscayne Blvd, Suite 201, Aventura, FL 33180 Phone: 305-534-4747 Fax: 305-937-7726 | |
Giridhar S Talluri, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 21110 Biscayne Blvd Ste 403, Aventura, FL 33180 Phone: 305-918-0742 Fax: 305-918-0787 | |
Jonathan L Silberstein, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 20801 Biscayne Blvd Ste 203, Aventura, FL 33180 Phone: 305-682-2580 Fax: 305-705-1677 | |
Floyd E Seskin, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 21097 Ne 27th Ct, Suite 101, Aventura, FL 33180 Phone: 305-792-6905 Fax: 305-792-6908 | |
Dr. Richard David Levin, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 21355 E Dixie Hwy, Suite 102, Aventura, FL 33180 Phone: 305-932-4444 | |
Mark B Weitzenfeld, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 21110 Biscayne Blvd, Suite 401, Aventura, FL 33180 Phone: 305-933-1772 Fax: 305-675-2788 | |
Dr. Arnon Krongrad, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 20900 Ne 30th Ave, Suite 207, Aventura, FL 33180 Phone: 305-936-0474 Fax: 305-936-0498 |